Why Spruce Biosciences Shares Are Trading Higher By 100%? Here Are Other Stocks Moving In Friday's Mid-Day Session

Gainers

• Swvl Holdings Corp. (NASDAQ:SWVL) surged 133% to $0.3218. Swvl recently announced the commencement of a strategic review process.
• Spruce Biosciences, Inc. (NASDAQ:SPRB) shares jumped 100.8% to $2.51. Spruce Biosciences and Kaken Pharmaceutical reported an exclusive licensing agreement to develop and commercialize Tildacerfont for CAH in Japan.
• MedAvail Holdings, Inc. (NASDAQ:MDVL) gained 54% to $0.4745. MedAvail Holdings, during November, posted a Q3 loss of $0.15 per share.
• CytomX Therapeutics, Inc. (NASDAQ:CTMX) climbed 46.4% to $2.6198. CytomX and Moderna reported a strategic research collaboration for mRNA-based conditionally activated therapeutics.
• Zomedica Corp. (NYSE:ZOM) gained 38% to $0.2649 after Dawson James initiated coverage on the stock with a Buy rating and a $6 price target.
• Aehr Test Systems (NASDAQ:AEHR) shares jumped 34.8% to $23.28 after the company reported better-than-expected Q2 EPS and sales results and announced it received a follow-on production order from its second major silicon carbide semiconductor customer for an additional production FOX-XP multi-wafer test and burn-in system configured with Aehr's fully integrated and automated WaferPak Aligner.
• Tantech Holdings Ltd (NASDAQ:TANH) gained 26.8% to $3.1980. Tantech Hldgs recently posted H1 sales of $27.00 million.
• Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) gained 26% to $0.7555.
• Aligos Therapeutics, Inc. (NASDAQ:ALGS) jumped 23.2% to $1.22 after Jefferies upgraded the stock from Hold to Buy and raised its price target from $2.5 to $3.
• Infobird Co., Ltd (NASDAQ:IFBD) surged 23% to $0.9476.
• Kidpik Corp. (NASDAQ:PIK) gained 22.2% to $0.8799.
• Sight Sciences, Inc. (NASDAQ:SGHT) gained 21.8% to $14.39. Stifel upgraded Sight Sciences from Hold to Buy and raised the price target from $10 to $15.
• Mobile Global Esports Inc. (NASDAQ:MGAM) rose 21.5% to $1.30 after gaining over 21% on Thursday.
• Schmitt Industries, Inc. (NASDAQ:SMIT) gained 21.3% to $0.3399.
• EZGO Technologies Ltd. (NASDAQ:EZGO) gained 19.5% to $0.99.
• Zynex, Inc. (NASDAQ:ZYXI) gained 19.4% to $16.89. Piper Sandler upgraded Zynex from Neutral to Overweight and raised the price target from $10 to $18.
• CureVac N.V. (NASDAQ:CVAC) surged 18.2% to $7.54 after the company announced data on joint COVID-19 and flu mRNA vaccine development programs.
• World Wrestling Entertainment, Inc. (NYSE:WWE) rose 17.6% to $84.69 after Vince McMahon announced he has taken actions in support of a plan for WWE to undertake a review of strategic alternatives and capture unique opportunity to maximize long-term value.
• Oxbridge Re Holdings Limited (NASDAQ:OXBR) gained 16.8% to $1.80.
• Sensus Healthcare, Inc. (NASDAQ:SRTS) jumped 16.6% to $8.60. Sensus Healthcare expects Q4 sales to exceed $13 million.
• TCR2 Therapeutics Inc. (NASDAQ:TCRR) gained 16.5% to $1.27. Piper Sandler maintained TCR2 Therapeutics with an Overweight and raised the price target from $8 to $10.
• Magic Empire Global Limited (NASDAQ:MEGL) rose 13.9% to $2.6199 after climbing 75% on Thursday.
• Mullen Automotive, Inc. (NASDAQ:MULN) gained 13.8% to $0.4762.
• Aethlon Medical, Inc. (NASDAQ:AEMD) shares rose 13.2% to $0.39. Aethlon Medical, last month, posted a Q2 loss of $0.18 per share.
• Duck Creek Technologies, Inc. (NYSE:DCT) gained 12.5% to $12.69 following Q1 results.
• Amarin Corporation plc (NASDAQ:AMRN) gained 12.3% to $1.4150 after Jefferies upgraded the stock from Hold to Buy and raised its price target from $1.3 to $3.
• JinkoSolar Holding Co., Ltd. (NYSE:JKS) rose 11.8% to $44.69.
• Immunome, Inc. (NASDAQ:IMNM) shares gained 11.2% to $5.24 after the company and AbbVie announced a strategic collaboration to discover multiple novel oncology targets. Immunome will receive a $30 million upfront payment with the potential for milestones and royalties.
• Oriental Culture Holding LTD (NASDAQ:OCG) gained 10% to $0.55.
• eFFECTOR Therapeutics, Inc. (NASDAQ:EFTR) rose 8% to $0.5958. eFFECTOR Therapeutics provided an update on its ongoing clinical development programs for zotatifin, in Phase 2 expansion cohorts for estrogen receptor-positive breast cancer (ER+ BC) and KRAS non-small cell lung cancer (KRAS NSCLC) as well as Phase 1 development for COVID-19, and tomivosertib, in Phase 2b trial for non-small cell lung cancer (NSCLC) in combination with pembrolizumab.

Losers

• Fate Therapeutics, Inc. (NASDAQ:FATE) shares dipped 62.2% to $4.16 after the company announced termination
• of its collaboration agreement with Janssen, pipeline prioritization, next-generation programs and key 2023 initiatives.
• Graphite Bio, Inc. (NASDAQ:GRPH) fell 41.3% to $1.7950 after the company reported it is voluntarily pausing the Phase 1/2 CEDAR study of nulabeglogene autogedtemcel (nula-cel) for sickle cell disease due to a serious adverse event in the first patient dosed with nula-cel.
• Atai Life Sciences N.V. (NASDAQ:ATAI) fell 41.3% to $1.5450 after the company announced Perception Neuroscience's Phase 2a clinical trial did not meet its primary endpoint.
• Nabriva Therapeutics plc (NASDAQ:NBRV) dropped 33.4% to $1.5238 after the company issued a corporate update.
• AnaptysBio, Inc. (NASDAQ:ANAB) declined 28.8% to $21.49 after the company announced portfolio update across best-in-class immune cell modulating antibodies. Raymond James downgraded AnaptysBio from Outperform to Market Perform.
• NextPlay Technologies, Inc. (NASDAQ:NXTP) fell 25.9% to $1.63. NextPlay announced a 1-for-20 reverse stock split effective January 6, 2023.
• Landos Biopharma, Inc. (NASDAQ:LABP) fell 24.7% to $0.4086 after Jefferies downgraded the stock from Hold to Underperform and lowered its price target from $0.20 to $0.10.
• AMTD Digital Inc. (NYSE:HKD) shares fell 24.5% to $22.54 after surging around 200% on Thursday.
• Elevation Oncology, Inc. (NASDAQ:ELEV) declined 20% to $0.8395 after the company reported pipeline prioritization, realignment of resources to advance EO-3021 and CEO transition.
• Tian Ruixiang Holdings Ltd (NASDAQ:TIRX) dropped 20% to $2.60.
• Vivos Therapeutics, Inc. (NASDAQ:VVOS) dropped 19.1% to $1.52. Vivos Therapeutics priced an $8 million private placement at $1.20 per unit.
• Moolec Science SA (NASDAQ:MLEC) declined 17.8% to $4.50.
• Genprex, Inc. (NASDAQ:GNPX) dropped 17.6% to $1.4225.
• Bed Bath & Beyond Inc. (NASDAQ:BBBY) fell 16.9% to $1.4050 after dropping around 30% on Thursday. The company said it will miss its 10-Q filing deadline for the quarter ending Nov 26, 2022 and has also concluded that there is substantial doubt about its ability to continue as a going concern.
• Kiora Pharmaceuticals, Inc. (NASDAQ:KPRX) declined 15.4% to $3.90.
• XPeng Inc. (NYSE:XPEV) fell 15% to $10.11.
• Palisade Bio, Inc. (NASDAQ:PALI) dropped 14.8% to $2.76.
• Eloxx Pharmaceuticals, Inc. (NASDAQ:ELOX) fell 14.5% to $3.6913.
• The Greenbrier Companies, Inc. (NYSE:GBX) dropped 14% to $30.00 after the company reported Q1 earnings results and issued guidance.
• Kura Sushi USA, Inc. (NASDAQ:KRUS) fell 13% to $42.11 after the company reported worse-than-expected Q1 EPS and sales results.
• InMed Pharmaceuticals Inc. (NASDAQ:INM) fell 13% to $1.68 after declining over 11% on Thursday.
• Vyant Bio, Inc. (NASDAQ:VYNT) fell 12.3% to $1.06. Vyant Bio shares jumped around 57% on Thursday after the company engaged LifeSci Capital as its advisor to explore strategic alternatives.
• Orchard Therapeutics plc (NASDAQ:ORTX) shares fell 11.3% to $0.5583. Orchard Therapeutics shares gained around 22% on Thursday after the company announced FDA clearance of the IND application for OTL-203 in MPS-IH.
• ABVC BioPharma, Inc. (NASDAQ:ABVC) fell 11.2% to $0.9501. ABVC BioPharma shares climbed over 72% on Thursday after the company announced the FDA approved its IND submission, allowing the company to proceed with the clinical study of ABV-1519 for the treatment of non-small cell lung cancer.
• Waters Corporation (NYSE:WAT) declined 9.9% to $312.79. SVB Leerink maintained Waters with a Market Perform and raised the price target from $320 to $352.
• Silvergate Capital Corporation (NYSE:SI) dropped 9.5% to $11.37 after multiple firms downgraded the stock and lowered their respective price target.

Also Check This Out Ethereum Remains Above This Key Level; TRON Becomes Top Loser